Abiomed (FRA:AIO) Tax Provision : €-71 Mil (TTM As of Sep. 2022)

View and export this data going back to 1987. Start your Free Trial

What is Abiomed Tax Provision?

Abiomed's tax provision for the three months ended in Sep. 2022 was €-33 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2022 was €-71 Mil.

Abiomed Tax Provision Historical Data

The historical data trend for Abiomed's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed Tax Provision Chart

Abiomed Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Tax Provision

Get a 7-Day Free Trial

-39.15

-3.84

-48.70

-52.66

-49.08

Abiomed Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Tax Provision	Get a 7-Day Free Trial															-8.77	-10.73	-13.11	-14.44	-32.90

Abiomed Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-71 Mil.

Abiomed (FRA:AIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (FRA:AIO) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Cherry Hill Drive, Danvers, MA, USA, 01923

Website

https://www.abiomed.com

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.